An FDA panel votes 11-0 in favor of the risk/benefit assessment for Onyx Pharmaceuticals' (ONXX)...


An FDA panel votes 11-0 in favor of the risk/benefit assessment for Onyx Pharmaceuticals' (ONXX) Kyprolis (carfilzomib) cancer drug for multiple myeloma. ONXX shares have been halted since ~12:30, but Ligand Pharma (LGND), which is due to receive milestone payments and royalties for the drug, rose 12.8% during regular trading and is +3.8% AH.

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs